Effect of ketogenic diet plus dulaglutide on glucose and lipid metabolism in diabetes mellitus.
Pak J Pharm Sci · 2025
Last updated 2026-05-28In a study of 104 people with type 2 diabetes, those who followed a ketogenic diet along with the drug dulaglutide had better blood sugar control, lower blood fat levels, and improved insulin function compared to those who only took dulaglutide. After 6 months, the group on the combined treatment also reported better sleep quality and overall quality of life.
AI summary of the abstract below.
| Journal | Pak J Pharm Sci, 2025 |
|---|---|
| Citations | 0 |
| Molecules | dulaglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Diabetes mellitus is a chronic disease with a high incidence worldwide and exclusive drug treatment has a limited effect. To investigate the effects of a ketogenic diet combined with dulaglutide on glucose and lipid metabolism in diabetic patients, a total of 104 patients with type 2 diabetes mellitus were randomly divided into a study group (dulaglutide + ketogenic diet) and a control group (dulaglutide). The results showed that, in comparison with the control group, the blood glucose and blood lipid levels in the study group were lower than those in the control group after treatment (P<0.05). The insulin resistance index of the study group was decreased and the insulin sensitivity index was increased (P<0.05). At the 6-month follow-up, the Pittsburgh Sleep Quality Index score was lower and the quality of life was better in the study group (P<0.05). In conclusion, thevketogenic diet combined with dulaglutide can effectively improve glucose and lipid metabolism, insulin function and quality of life in diabetes mellitus patients.
Verbatim abstract via PubMed 41241797 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).